Structure Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
GPCR$21.41+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| · · DECEMBER 31, | ||||||
| · 2023 · · 2022 | ||||||
| Assets · · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $129,792 | | $26,091 | ||
| Short-term investments | | 337,531 | | 64,750 | ||
| Prepaid expenses and other current assets | | 6,285 | | 2,248 | ||
| Total current assets | | 473,608 | | 93,089 | ||
| Property and equipment, net | | 3,228 | | 1,031 | ||
| Operating right-of-use assets | | 5,136 | | 262 | ||
| Other non-current assets | | 45 | | 3,463 | ||
| Total assets | | $482,017 | | $97,845 | ||
| Liabilities, redeemable convertible preferred shares and shareholders’ equity (deficit) | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $4,742 | | $6,009 | ||
| Accrued expenses and other current liabilities | | 18,558 | | 6,741 | ||
| Operating lease liabilities, current portion | | 1,440 | | 260 | ||
| Total current liabilities | | 24,740 | | 13,010 | ||
| Operating lease liabilities, net of current portion | | | 4,013 | | | — |
| Other non-current liabilities | | | 298 | | | — |
| Total liabilities | | 29,051 | | 13,010 | ||
| Commitments and contingencies (Note 6) | | | ||||
| Series A redeemable convertible preferred shares – $0.0001 par value, 0 and 19,200 shares authorized, issued and outstanding as of December 31, 2023 and December 31, 2022, respectively (liquidation preference of $0 and $32,001 as of December 31, 2023 and December 31, 2022, respectively) | | — | | 32,001 | ||
| Series A+ redeemable convertible preferred shares – $0.0001 par value, 0 and 12,800 shares authorized, issued and outstanding as of December 31, 2023 and December 31, 2022, respectively (liquidation preference of $0 and $26,000 as of December 31, 2023 and December 31, 2022, respectively ) | | — | | 26,000 | ||
| Series B redeemable convertible preferred stock – $0.0001 par value, 0 and 32,857 shares authorized, issued and outstanding as of December 31, 2023 and December 31, 2022, respectively (liquidation preference of $0 and $133,015 as of December 31, 2023 and December 31, 2022, respectively) | | — | | 133,015 | ||
| Series B‑1 redeemable convertible preferred stock – $0.0001 par value, 0 and 2,161 shares authorized, issued and outstanding as of December 31, 2023 and December 31, 2022, respectively (liquidation preference of $0 and $7,000 as of December 31, 2023 and December 31, 2022, respectively) | | — | | 8,959 | ||
| Shareholders’ equity (deficit): | | | ||||
| Undesignated shares – $0.0001 par value; 90,188 and 0 shares authorized as of December 31, 2023 and December 31, 2022, respectively | | | — | | | — |
| Ordinary shares – $0.0001 par value; 500,000 and 432,982 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 139,220 and 10,527 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | | 14 | | 1 | ||
| Additional paid-in capital | | 659,003 | | 1,921 | ||
| Accumulated other comprehensive income (loss) | | 521 | | (110) | ||
| Accumulated deficit | | (206,572) | | (116,952) | ||
| Total shareholders’ equity (deficit) | | 452,966 | | (115,140) | ||
| Total liabilities, redeemable convertible preferred shares and shareholders’ equity (deficit) | | $482,017 | | $97,845 | ||
| | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.